Literature DB >> 26681901

Pharmaceutical Approval Update.

Chris Fellner.   

Abstract

Idarucizumab (Praxbind) to reverse the anticoagulant effects of dabigatran (Pradaxa); aripiprazole lauroxil (Aristada) for the treatment of schizophrenia; and insulin degludec injection (Tresiba) for diabetes.

Entities:  

Year:  2015        PMID： 26681901      PMCID： PMC4671464     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  3 in total

1.  Idarucizumab (Praxbind) for reversal of pradaxa prior to emergent repair of contained ruptured transverse arch aneurysm.

Authors:  Erol Vahit Belli; Teng Lee
Journal:  Ann Card Anaesth       Date:  2017 Jul-Sep

Review 2.  Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review.

Authors:  Kunal Maini; Haley Gould; Jessica Hicks; Fatima Iqbal; James Patterson; Amber N Edinoff; Elyse M Cornett; Adam M Kaye; Omar Viswanath; Ivan Urits; Alan D Kaye
Journal:  Neurol Int       Date:  2021-07-01

3.  The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) : Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands.

Authors:  V Ten Cate; H Ten Cate; F W A Verheugt
Journal:  Neth Heart J       Date:  2016-10       Impact factor: 2.380
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.